Kaplan–Meier curves for PFS of patients classified by the presence or absence of plasma EGFR mutations both at pretreatment (P0) and at 6 weeks from the start of study treatment (P1). HR, hazard ratio. BE, bevacizumab and erlotinib combination therapy arm; E, erlotinib monotherapy arm. A. type A, neither detectable at P0 nor at P1; B. type B, detectable at P0 and disappeared at P1; C. type C, detectable both at P0 and P1.